Cargando…

Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections

Telavancin, a novel lipoglycopeptide with rapid concentration-dependent bactericidal effects, is a semisynthetic derivative of the glycopeptide, vancomycin. Telavancin has a dual mechanism of action, ie, inhibition of peptidoglycan polymerization and disruption of the bacterial membrane. It has line...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jafari Saraf, Lida, Wilson, Samuel Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108747/ https://www.ncbi.nlm.nih.gov/pubmed/21694912 http://dx.doi.org/10.2147/IDR.S5327

Ejemplares similares

Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)

Recurrence of skin infections in patients treated with telavancin versus vancomycin for complicated skin and soft tissue infections in a New Orleans emergency department
por: Dunbar, L, et al.
Publicado: (2008)

Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics
por: Eckmann, Christian, et al.
Publicado: (2021)

Role of telavancin in treatment of skin and skin structure infections
por: Bonkowski, Joseph, et al.
Publicado: (2010)

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)
por: Dunbar, Lala M, et al.
Publicado: (2008)

Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts)
por: Barcia-Macay, Maritza, et al.
Publicado: (2008)

Efficacy of telavancin for treatment of surgical site infections
por: Wilson, SE, et al.
Publicado: (2008)

Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections
por: Brade, Karrine D., et al.
Publicado: (2016)

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Bressler, Adam M., et al.
Publicado: (2019)

Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles, et al.
Publicado: (2017)

Update on the emerging role of telavancin in hospital-acquired infections
por: Nnedu, Obinna N, et al.
Publicado: (2015)

Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles R., et al.
Publicado: (2021)

Meropenem in the treatment of complicated skin and soft tissue infections
por: Fish, Douglas N
Publicado: (2006)

Chemical Stability of Telavancin in Elastomeric Pumps()
por: Sand, Patrick, et al.
Publicado: (2015)

Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Reilly, Joseph, et al.
Publicado: (2020)

Specific Inhibition of VanZ-Mediated Resistance to Lipoglycopeptide Antibiotics
por: Sur, Vishma Pratap, et al.
Publicado: (2021)

Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections
por: Plaunt, Adam J., et al.
Publicado: (2021)

Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections
por: Smith, Jordan R., et al.
Publicado: (2015)

Long-Acting Lipoglycopeptides: “Lineless Antibiotics” for Serious Infections in Persons Who Use Drugs
por: Morrisette, Taylor, et al.
Publicado: (2019)

Linezolid in the treatment of HIV-infected patients with complicated skin and soft tissue infections
por: Khachatryan, N, et al.
Publicado: (2007)

Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review
por: Bennett, Jason W, et al.
Publicado: (2008)

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
por: al Jalali, Valentin, et al.
Publicado: (2018)

Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies
por: Wilson, Samuel E., et al.
Publicado: (2017)

2364. Evaluation of Renal Function Changes in Patients With Prolonged Telavancin Therapy (>21 Days): Results From the Telavancin Observational Use Registry (TOUR™)
por: Hassoun, Ali, et al.
Publicado: (2018)

617. Long Acting Lipoglycopeptide Use in Veterans for Serious Gram-Positive Infections in the COVID Era
por: Saldana, Carlos S, et al.
Publicado: (2021)

Preclinical Investigation of a Lipoglycopeptide Dry Powder Inhalation Therapy for the Treatment of Pulmonary MRSA Infection
por: Konicek, Donna M., et al.
Publicado: (2023)

Complicated skin, skin structure and soft tissue infections - are we threatened by multi-resistant pathogens?
por: Kujath, P, et al.
Publicado: (2010)

Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin
por: White, Beth, et al.
Publicado: (2011)

Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia
por: Mpenge, Mbiye A, et al.
Publicado: (2015)

Comparative In Vitro Activity of New Lipoglycopeptides and Vancomycin Against Ocular Staphylococci and Their Toxicity on the Human Corneal Epithelium
por: André, Camille, et al.
Publicado: (2023)

Impact of the new membrane-targeting lipoglycopeptide antibiotic MCC5145 on the treatment of bacteremic pneumococcal pneumonia in mice
por: Ogunniyi, Abiodun D., et al.
Publicado: (2023)

Evaluation of telavancin dose capping in a large community hospital
por: Hassoun, Ali, et al.
Publicado: (2017)

291 Efficacy and safety of telavancin in the treatment ofram-positive bloodstream infections in cancer patients
por: Chaftari, Anne-Marie, et al.
Publicado: (2014)

Engineered biosynthesis of enduracidin lipoglycopeptide antibiotics using the ramoplanin mannosyltransferase Ram29
por: Wu, Ming-Cheng, et al.
Publicado: (2015)

231. Retrospective Comparison of Intravenous Therapy, Oral Therapy, and Lipoglycopeptides for the Treatment of Osteomyelitis
por: Stumphauzer, Alex, et al.
Publicado: (2021)

Staphylococcus aureus is able to generate resistance to novel lipoglycopeptide antibiotic gausemycin A
por: Poshvina, Darya V., et al.
Publicado: (2022)

The novel antimicrobial peptide PXL150 in the local treatment of skin and soft tissue infections
por: Myhrman, Emma, et al.
Publicado: (2012)

Skin and soft tissue infections in the elderly
por: Falcone, Marco, et al.
Publicado: (2023)

456. Dalbavancin, a Long-Acting Lipoglycopeptide Antimicrobial Agent, Reduces Length of Stay and Improves Patient Work Productivity in a Hospital Critical Pathway for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)—the ENHANCE ABSSSI Trial
por: McCarthy, Matthew W, et al.
Publicado: (2019)

Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections
por: Das, Shampa, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bbsn30d6e2p5kvf6a8o9ocni5h